{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:28:21Z","timestamp":1745861301284},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-953","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T02:40:30Z","timestamp":1434595230000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin\u2013gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study"],"prefix":"10.1186","volume":"14","author":[{"given":"Isabelle","family":"Borget","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Lavol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"D\u00f4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacky","family":"Crequit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"L\u00e9na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Le Caer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Falchero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Poudenx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Vaylet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Vergnenegre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Choua\u00efd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,15]]},"reference":[{"key":"5140_CR1","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1200\/JCO.2009.23.1183","volume":"27","author":"NJ Meropol","year":"2009","unstructured":"Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE, American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol. 2009, 27: 3868-3874. 10.1200\/JCO.2009.23.1183.","journal-title":"J Clin Oncol"},{"key":"5140_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/00019053-200927020-00003","volume":"27","author":"C Chouaid","year":"2009","unstructured":"Chouaid C, Atsou K, Hejblum G, Vergnenegre A: Economics of treatments for non-small cell lung cancer. Pharmacoeconomics. 2009, 27: 113-125. 10.2165\/00019053-200927020-00003.","journal-title":"Pharmacoeconomics"},{"key":"5140_CR3","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1200\/JCO.2010.34.2774","volume":"29","author":"CG Azzoli","year":"2011","unstructured":"Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G, American Society of Clinical Oncology: 2011 focused update of 2009 American Society of Clinical Oncology Clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. American Society of Clinical Oncology. J Clin Oncol. 2011, 29: 3825-3831. 10.1200\/JCO.2010.34.2774.","journal-title":"J Clin Oncol"},{"key":"5140_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/CCO.0b013e328322cf49","volume":"21","author":"SI Jalal","year":"2009","unstructured":"Jalal SI, Ademuyiwa FO, Hanna NH: The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2009, 21: 110-115. 10.1097\/CCO.0b013e328322cf49.","journal-title":"Curr Opin Oncol"},{"key":"5140_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.lungcan.2006.01.006","volume":"52","author":"T Brodowicz","year":"2006","unstructured":"Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M, Central European Cooperative Oncology Group CECOG: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006, 52: 155-163. 10.1016\/j.lungcan.2006.01.006.","journal-title":"Lung Cancer"},{"key":"5140_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jnci\/dji096","volume":"97","author":"V Westeel","year":"2005","unstructured":"Westeel V, Quoix E, Moro-Sibilot D, Mercier M, Breton JL, Debieuvre D, Richard P, Haller MA, Milleron B, Herman D, Level MC, Lebas FX, Puyraveau M, Depierre A: Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005, 97: 499-506. 10.1093\/jnci\/dji096.","journal-title":"J Natl Cancer Inst"},{"key":"5140_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","volume":"374","author":"T Ciuleanu","year":"2009","unstructured":"Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009, 374: 1432-1440. 10.1016\/S0140-6736(09)61497-5.","journal-title":"Lancet"},{"key":"5140_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2008.17.1405","volume":"27","author":"PM Fidias","year":"2009","unstructured":"Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009, 27: 591-598.","journal-title":"J Clin Oncol"},{"key":"5140_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"L Paz-Ares","year":"2012","unstructured":"Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012, 13: 247-255. 10.1016\/S1470-2045(12)70063-3.","journal-title":"Lancet Oncol"},{"key":"5140_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol. 2009, 27: 1227-1234. 10.1200\/JCO.2007.14.5466.","journal-title":"J Clin Oncol"},{"key":"5140_CR11","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"AB Sandler","year":"2006","unstructured":"Sandler AB, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006, 355: 2542-2550. 10.1056\/NEJMoa061884.","journal-title":"N Engl J Med"},{"key":"5140_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","volume":"373","author":"R Pirker","year":"2009","unstructured":"Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U, FLEX Study Team: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009, 373: 1525-1531. 10.1016\/S0140-6736(09)60569-9.","journal-title":"Lancet"},{"key":"5140_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","volume":"11","author":"F Cappuzzo","year":"2010","unstructured":"Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szcz\u00e9sna A, Juh\u00e1sz E, Esteban E, Molinier O, Brugger W, Melez\u00ednek I, Klingelschmitt G, Klughammer B, Giaccone G, SATURN investigators: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11: 521-529. 10.1016\/S1470-2045(10)70112-1.","journal-title":"Lancet Oncol"},{"issue":"31","key":"5140_CR14","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1200\/JCO.2012.47.3983","volume":"31","author":"BE Johnson","year":"2013","unstructured":"Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V: A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013, 31 (31): 3926-3934. 10.1200\/JCO.2012.47.3983.","journal-title":"J Clin Oncol"},{"issue":"28","key":"5140_CR15","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1200\/JCO.2011.39.9782","volume":"30","author":"M P\u00e9rol","year":"2012","unstructured":"P\u00e9rol M, Choua\u00efd C, Milleron J, Barl\u00e9si F, Gervais R, Westeel V, Crequit J, L\u00e9na H, Vergnen\u00e8gre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, S\u00e9gura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B: Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol. 2012, 30 (28): 3516-3524. 10.1200\/JCO.2011.39.9782.","journal-title":"J Clin Oncol"},{"key":"5140_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/JTO.0b013e3181e15d16","volume":"5","author":"R Klein","year":"2010","unstructured":"Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, Schwartzberg L: Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010, 5: 1263-1272. 10.1097\/JTO.0b013e3181e15d16.","journal-title":"J Thorac Oncol"},{"key":"5140_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.lungcan.2011.11.005","volume":"76","author":"MJ Nuijten","year":"2012","unstructured":"Nuijten MJ, de Castro CJ, Choua\u00efd C, Vergnen\u00e8gre A, Grossi F, Bischoff H, Heigener D, Walzer S: A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer. 2012, 76: 465-471. 10.1016\/j.lungcan.2011.11.005.","journal-title":"Lung Cancer"},{"key":"5140_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jval.2011.08.1737","volume":"15","author":"K Matter-Walstra","year":"2012","unstructured":"Matter-Walstra K, Joerger M, K\u00fchnel U, Szucs T, Pestalozzi B, Schwenkglenks M: Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health. 2012, 15: 65-71. 10.1016\/j.jval.2011.08.1737.","journal-title":"Value Health"},{"key":"5140_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.lungcan.2011.04.002","volume":"74","author":"T Tsuchiya","year":"2011","unstructured":"Tsuchiya T, Fukuda T, Furuiye M, Kawabuchi K: Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. Lung Cancer. 2011, 74: 521-528. 10.1016\/j.lungcan.2011.04.002.","journal-title":"Lung Cancer"},{"key":"5140_CR20","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1200\/JCO.2011.37.8349","volume":"29","author":"FA Shepherd","year":"2011","unstructured":"Shepherd FA: Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?. J Clin Oncol. 2011, 29: 4068-4070. 10.1200\/JCO.2011.37.8349.","journal-title":"J Clin Oncol"},{"key":"5140_CR21","first-page":"72","volume":"50","author":"Minist\u00e8re de la Sant\u00e9 et des Solidarit\u00e9s","year":"2007","unstructured":"Minist\u00e8re de la Sant\u00e9 et des Solidarit\u00e9s: Arr\u00eat\u00e9 du 27 f\u00e9vrier 2007 relatif \u00e0 la classification et \u00e0 la prise en charge des prestations d\u2019hospitalisation pour les activit\u00e9s de m\u00e9decine, chirurgie, obst\u00e9trique et odontologie et pris en application de l\u2019article L. 162-22-6 du code de la s\u00e9curit\u00e9 sociale. J Officiel. 2007, 50: 72-","journal-title":"J Officiel"},{"key":"5140_CR22","unstructured":"Nomenclature G\u00e9n\u00e9rale des Actes Professionnels: Union des Caisses Nationales de S\u00e9curit\u00e9 Sociale (UCANSS). Paris. http:\/\/www.ameli.fr\/professionnels-de-sante\/directeurs-d-etablissements-de-sante\/codage\/ngap.php ,"},{"key":"5140_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.bjc.6601547","volume":"90","author":"C Choua\u00efd","year":"2004","unstructured":"Choua\u00efd C, Molinier L, Combescure C, Daur\u00e8s JP, Housset B, Vergnen\u00e8gre A: Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer. 2004, 90: 397-402. 10.1038\/sj.bjc.6601547.","journal-title":"Br J Cancer"},{"issue":"6","key":"5140_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"21","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J: Health state utilities for non-small cell lung cancer. Health Qual Life Outcomes. 2008, 21 (6): 84-","journal-title":"Health Qual Life Outcomes"},{"key":"5140_CR25","volume-title":"National Institute for Health and Clinical Excellence (NICE)","author":"National Institute for Health and Clinical Excellence appraising pemetrexed for the maintenance treatment of non-small-cell lung cancer London","year":"2009","unstructured":"National Institute for Health and Clinical Excellence appraising pemetrexed for the maintenance treatment of non-small-cell lung cancer London: National Institute for Health and Clinical Excellence (NICE). 2009, Available from: http:\/\/www.nice.org.uk\/guidance\/TA190"},{"key":"5140_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/CEOR.S25923","volume":"4","author":"A Vergnen\u00e8gre","year":"2012","unstructured":"Vergnen\u00e8gre A, Ray JA, Choua\u00efd C, Grossi F, Bischoff HG, Heigener DF, Walzer S: Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon Outcomes Res. 2012, 4: 31-37.","journal-title":"Clinicoecon Outcomes Res"},{"key":"5140_CR27","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/11591600-000000000-00000","volume":"29","author":"R Dickson","year":"2011","unstructured":"Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, Hockenhull J, Martin Saborido C, Oyee J, Ramani VS: Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. 2011, 29: 1051-1062. 10.2165\/11591600-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"5140_CR28","volume-title":"National Institute for Health and Clinical Excellence (NICE)","author":"National Institute for Health and Clinical Excellence appraising life-extending, end of life treatments. [Internet]. London","year":"2009","unstructured":"National Institute for Health and Clinical Excellence appraising life-extending, end of life treatments. [Internet]. London: National Institute for Health and Clinical Excellence (NICE). 2009"},{"key":"5140_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.seminoncol.2013.12.013","volume":"41","author":"S Carnio","year":"2014","unstructured":"Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV: Extending survival of stage IV non-small cell lung cancer. Semin Oncol. 2014, 41: 69-92. 10.1053\/j.seminoncol.2013.12.013.","journal-title":"Semin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-953.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-953\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T17:45:41Z","timestamp":1468345541000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["5140"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-953","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"article-number":"953"}}